← Back to Clinical Trials
Recruiting NCT07731126

NCT07731126 New Care Pathways for Supporting TRANSitional CARE From Hospital to Home Using AI and Personalized Digital Assistance

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07731126
Status Recruiting
Phase
Sponsor Istituto Nazionale di Ricovero e Cura per Anziani
Condition Transitional Care
Study Type INTERVENTIONAL
Enrollment 210 participants
Start Date 2025-12-12
Primary Completion 2027-02-28

Eligibility & Interventions

Sex All sexes
Min Age 65 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
TRANSCARE Digital Remote Monitoring Ecosystem

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 210 participants in total. It began in 2025-12-12 with a primary completion date of 2027-02-28.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The objective of the TRANSCARE study is to evaluate the use of a digital remote monitoring system to reduce the risk of 30-day readmission in multimorbid elderly patients. The pilot study is multicenter, and the trial will be conducted across 3 sites: Italy, Romania, and Norway. The overall goal of the TRANSCARE project is to create a digital monitoring ecosystem capable of identifying and preventing the risk of readmission. Two hundred and ten older adults aged over 65, who meet the inclusion and exclusion criteria, will be enrolled in the study. They will be randomized into two groups and allocated to an intervention group or a control group.

Eligibility Criteria

Inclusion Criteria: * Able to stand and walk even with support; * Mini Mental State Examination (MMSE) ≥ 18; * Clinical Frailty Scale (CFS) score 2-7; Exclusion Criteria: * Allergy to nichel components; * Concomitant participation in other studies; * Severe dementia condition * Mild to moderate dementia condition in the absence of the caregiver * Terminal chronic renal failure with the need for dialysis * Inability or unwillingness to sign written informed consent; * Pacemaker or implantable cardioverter defibrillator; * Metastatic cancer or immunosuppressive therapy; * Significant visual or hearing impairment; * Severe systemic diseases with life expectancy \< 6 year; * Move to nursing home after discharge

Contact & Investigator

Central Contact

Anna Rita Bonfigli, PhD

✉ a.bonfigli@inrca.it

📞 0718003719

Principal Investigator

Ionut Anghel, Prof. Dr.

STUDY CHAIR

Technical University of Cluj-Napoca, Romania

Frequently Asked Questions

Who can join the NCT07731126 clinical trial?

This trial is open to participants of all sexes, aged 65 Years or older, studying Transitional Care. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07731126 currently recruiting?

Yes, NCT07731126 is actively recruiting participants. Contact the research team at a.bonfigli@inrca.it for enrollment information.

Where is the NCT07731126 trial being conducted?

This trial is being conducted at Ancona, Italy, Farsund, Norway, Cluj-Napoca, Romania.

Who is sponsoring the NCT07731126 clinical trial?

NCT07731126 is sponsored by Istituto Nazionale di Ricovero e Cura per Anziani. The principal investigator is Ionut Anghel, Prof. Dr. at Technical University of Cluj-Napoca, Romania. The trial plans to enroll 210 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology